Stock Events

Stock Events

DiaMedica Therapeutics 

$6.73
18
+$0.17+2.59% 17:13 Today

Statistics

Day High
6.74
Day Low
6.59
52W High
10.42
52W Low
5.25
Volume
310
Avg. Volume
-
Mkt Cap
362.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.21
-0.19
-0.18
-0.16
Expected EPS
-0.2075
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-32.77MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMAC. It's not an investment recommendation.
NVIDIA
5
NVDA
Apple
3
AAPL
Alphabet
3
GOOGL
Schwab US Dividend Equity
3
SCHD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative therapies for serious and life-threatening rare diseases, competing in the same therapeutic areas as DiaMedica.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for the treatment of rare genetic diseases, overlapping with DiaMedica's focus on novel treatments for neurological and kidney diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, directly competing with DiaMedica's approach to treating diseases at the genetic level.
Akebia Therapeutics
AKBA
Mkt Cap243.47M
Akebia Therapeutics focuses on the development and commercialization of therapeutics for kidney disease, directly competing with DiaMedica's kidney disease treatment pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is known for its focus on treating serious, life-threatening diseases, including a range of therapies that could compete with DiaMedica's products.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious diseases, including areas that overlap with DiaMedica's interests.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neuroscience, developing therapies for neurological and neurodegenerative diseases, directly competing with DiaMedica's focus on neurological conditions.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, with a broad portfolio that can compete across several of DiaMedica's areas of interest.

About

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Show more...
CEO
Dietrich John Pauls
Employees
35
Country
Canada
ISIN
CA25253X2077

Listings

XNAS
US
DMAC
BOATS
BOATS
DMAC.BOATS

0 Comments

Share your thoughts

FAQ

What is DiaMedica Therapeutics stock price today?▼
The current price of DMAC is $6.73 USD — it has increased by +2.59% in the past 24 hours. Watch DiaMedica Therapeutics stock price performance more closely on the chart.
What is DiaMedica Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange DiaMedica Therapeutics stocks are traded under the ticker DMAC.
Is DiaMedica Therapeutics stock price growing?▼
DMAC stock has risen by +4.93% compared to the previous week, the month change is a +2.52% rise, over the last year DiaMedica Therapeutics has showed a +24.86% increase.
What is DiaMedica Therapeutics market cap?▼
Today DiaMedica Therapeutics has the market capitalization of 362.92M
When is the next DiaMedica Therapeutics earnings date?▼
DiaMedica Therapeutics is going to release the next earnings report on November 18, 2026.
What were DiaMedica Therapeutics earnings last quarter?▼
DMAC earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.2 USD resulting in a +5.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is DiaMedica Therapeutics revenue for the last year?▼
DiaMedica Therapeutics revenue for the last year amounts to 0 USD.
What is DiaMedica Therapeutics net income for the last year?▼
DMAC net income for the last year is -32.77M USD.
How many employees does DiaMedica Therapeutics have?▼
As of September 04, 2026, the company has 35 employees.
In which sector is DiaMedica Therapeutics located?▼
DiaMedica Therapeutics operates in the Health & Wellness sector.
When did DiaMedica Therapeutics complete a stock split?▼
The last stock split for DiaMedica Therapeutics was on November 15, 2018 with a ratio of 1:20.
Where is DiaMedica Therapeutics headquartered?▼
DiaMedica Therapeutics is headquartered in MINNEAPOLIS, Canada.